• Shang-Yi Huang, Hsiu-Hsia Lin, Ming Yao, Jih-Luh Tang, Shang-Ju Wu, Wen-Chien Chou, Szu-Chun Hsu, Bor-Sheng Ko, and Hwei-Fang Tien.
• Department of Internal Medicine, National Taiwan University, Medical College and Hospital, Taiwan. Electronic address: syhuang55@ntuh.gov.tw.
• J Formos Med Assoc. 2022 Mar 1; 121 (3): 643-651.

Background/PurposeDecorin is a small leucine-rich proteoglycan rich in extracellular matrix with potential antitumor activity. However, the role of decorin in hematological malignancies remains unclear, especially in the case of multiple myeloma (MM), a bone marrow (BM) stroma-dependent plasma cell neoplasm.MethodsWe measured decorin levels in BM plasma samples from 270 patients with newly diagnosed MM (NDMM) using enzyme-linked immunosorbent assays.ResultsPatients were divided into high decorin (H-DCN, > 18.99 ng/mL) and low decorin (L-DCN <9.76 ng/mL) groups. Patients in the H-DCN group had more advanced-stage disease, including more osteolysis terms of higher levels of C-terminal telopeptides of type I collagen (0.69 ± 0.55 vs. 0.49 ± 0.36 ng/mL; P = 0.028), than those in the L-DCN group. Decorin levels correlated positively with hepatocyte growth factor (HGF) levels in BM plasma samples from NDMM patients (Pearson correlation coefficient, 0.226; P < 0.001). Patients with low HGF (<0.79 ng/mL) but high decorin levels (≥12.95 ng/mL) had a higher treatment response rate (90.5% vs. 54.5%, respectively; P = 0.015) and improved overall survival (not reached vs. 53 months; P = 0.0148) than those with lower decorin levels (<12.95 ng/mL). Multivariate analysis confirmed that a high decorin level was an independent predictive factor for treatment response and survival in patients with low HGF levels.ConclusionOur findings suggest that decorin may exert protective effects in this subset of MM patients.Copyright © 2021 Formosan Medical Association. Published by Elsevier B.V. All rights reserved.

16 keywords...

hide…